{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:55:26Z","timestamp":1759481726862},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1016\/j.berh.2004.11.003","type":"journal-article","created":{"date-parts":[[2005,4,27]],"date-time":"2005-04-27T11:41:43Z","timestamp":1114602103000},"page":"307-320","source":"Crossref","is-referenced-by-count":9,"title":["How can relapses be detected and prevented in primary systemic small-vessel vasculitides?"],"prefix":"10.1016","volume":"19","author":[{"given":"Carol A.","family":"Langford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2004.11.003_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00002281-200201000-00005","article-title":"Assessing disease activity in the systemic vasculitides","volume":"14","author":"Luqmani","year":"2002","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.berh.2004.11.003_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2004.11.003_bib3","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0272-6386(03)00025-8","article-title":"Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study","volume":"41","author":"Booth","year":"2003","journal-title":"Am J Kid Dis"},{"key":"10.1016\/j.berh.2004.11.003_bib4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0002-9343(99)00064-9","article-title":"Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis","volume":"106","author":"Kyndt","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.berh.2004.11.003_bib5","first-page":"127","article-title":"ANCA and predicting relapse in systemic vasculitis","volume":"88","author":"Jayne","year":"1995","journal-title":"QJM"},{"key":"10.1016\/j.berh.2004.11.003_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00005792-199901000-00003","article-title":"Churg\u2013Strauss syndrome. Clinical study and long-term follow-up of 96 patients","volume":"78","author":"Guillevin","year":"1999","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.berh.2004.11.003_bib7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/qjmed\/90.5.367","article-title":"Infections and Wegener's granulomatosis\u2014a cause and effect relationship?","volume":"90","author":"George","year":"1997","journal-title":"QJM"},{"key":"10.1016\/j.berh.2004.11.003_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/srin.2003.50002","article-title":"Does infection play a role in the pathogenesis of pulmonary vasculitis?","volume":"18","author":"Capizzi","year":"2003","journal-title":"Semin Resp Inf"},{"key":"10.1016\/j.berh.2004.11.003_bib9","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-113-9-656","article-title":"Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis","volume":"113","author":"Falk","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2004.11.003_bib10","first-page":"1524","article-title":"Seasonal variation in the onset of Wegener's granulomatosis, polyarteritis nodosa and giant cell arteritis","volume":"20","author":"Raynauld","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2004.11.003_bib11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/art.1780390112","article-title":"The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources","volume":"39","author":"Cotch","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2004.11.003_bib12","first-page":"669","article-title":"Wegener's granulomatosis: role of environmental exposures","volume":"16","author":"Duna","year":"1998","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2004.11.003_bib13","first-page":"121","article-title":"Mercuric chloride-treated brown Norway rats develop widespread tissue injury including necrotizing vasculitis","volume":"67","author":"Mathieson","year":"1992","journal-title":"Lab Investig"},{"key":"10.1016\/j.berh.2004.11.003_bib14","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1002\/(SICI)1521-4141(199807)28:07<2217::AID-IMMU2217>3.0.CO;2-P","article-title":"Myeloperoxidase autoantibodies distinguish vasculitis mediated by anti-neutrophil cytoplasm antibodies from immune complex disease in MRL\/Mp-lpr\/lpr mice: a spontaneous model for human microscopic angiitis","volume":"28","author":"Harper","year":"1998","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.berh.2004.11.003_bib15","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0889-857X(05)70237-4","article-title":"Are antineutrophil cytoplasmic antibodies pathogenic? Experimental approaches to understand the antineutrophil cytoplasmic antibody phenomenon","volume":"27","author":"Russell","year":"2001","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.berh.2004.11.003_bib16","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/bmj.281.6244.836","article-title":"Relapses in Wegener's granulomatosis: the role of infection","volume":"281","author":"Pinching","year":"1980","journal-title":"BMJ"},{"key":"10.1016\/j.berh.2004.11.003_bib17","first-page":"779","article-title":"Relapses in patients with a systemic vasculitis","volume":"86","author":"Gordon","year":"1993","journal-title":"QJM"},{"key":"10.1016\/j.berh.2004.11.003_bib18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.7326\/0003-4819-120-1-199401010-00003","article-title":"Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis","volume":"120","author":"Stegeman","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2004.11.003_bib19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM199607043350103","article-title":"Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis","volume":"335","author":"Stegeman","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2004.11.003_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/ar392","article-title":"Staphylococcus aureus and Wegener's granulomatosis","volume":"4","author":"Popa","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1016\/j.berh.2004.11.003_bib21","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2169\/internalmedicine.42.771","article-title":"The relation between Staphylococcus aureus and Wegener's granulomatosis: current knowledge and future directions","volume":"42","author":"Popa","year":"2003","journal-title":"Intern Med"},{"key":"10.1016\/j.berh.2004.11.003_bib22","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0140-6736(85)91147-X","article-title":"Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis","volume":"1","author":"van der Woude","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2004.11.003_bib23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.7326\/0003-4819-111-1-28","article-title":"Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener's granulomatosis","volume":"111","author":"N\u00f6lle","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2004.11.003_bib24","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1001\/archinte.149.11.2461","article-title":"Association between active Wegener's granulomatosis and anticytoplasmic antibodies","volume":"149","author":"Cohen Tervaert","year":"1989","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.berh.2004.11.003_bib25","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1681\/ASN.V1371977","article-title":"ANCA are pathogenic\u2014oh yes they are!","volume":"13","author":"Falk","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.berh.2004.11.003_bib26","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1172\/JCI0215918","article-title":"Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice","volume":"110","author":"Xiao","year":"2002","journal-title":"J Clin Investig"},{"key":"10.1016\/j.berh.2004.11.003_bib27","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/0272-6386(95)90098-5","article-title":"Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis","volume":"25","author":"De'Oliviera","year":"1995","journal-title":"Am J Kid Dis"},{"key":"10.1016\/j.berh.2004.11.003_bib28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/rheumatology\/40.2.147","article-title":"Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study","volume":"40","author":"Girard","year":"2001","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2004.11.003_bib29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0002-9343(03)00077-9","article-title":"Use of a cyclophosphamide induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse","volume":"114","author":"Langford","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.berh.2004.11.003_bib30","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO;2-O","article-title":"Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study","volume":"43","author":"Boomsma","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2004.11.003_bib31","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/1529-0131(199912)42:12<2666::AID-ANR24>3.0.CO;2-E","article-title":"A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance","volume":"42","author":"Langford","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2004.11.003_bib32","first-page":"80","article-title":"Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis","volume":"30","author":"Koldingsnes","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2004.11.003_bib33","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/art.11075","article-title":"Wegener's granulomatosis etanercept trial research G. limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial","volume":"48","author":"Stone","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2004.11.003_bib34","first-page":"S35","article-title":"New developments in the pathogenesis of ANCA-associated vasculitis","volume":"21","author":"Day","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2004.11.003_bib35","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.4049\/jimmunol.160.7.3602","article-title":"Active Wegener's granulomatosis is associated with HLA-DR+CD4+T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10","volume":"160","author":"Ludviksson","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.berh.2004.11.003_bib36","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1046\/j.1523-1755.2002.00619.x","article-title":"Expression profile of leukocyte genes activated by anti-neutrophil cytoplasmic autoantibodies (ANCA)","volume":"62","author":"Yang","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.berh.2004.11.003_bib37","first-page":"S3","article-title":"Mass spectrometry-based proteomics and analyses of serum: a primer for the clinical investigator","volume":"21","author":"Fusaro","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2004.11.003_bib38","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/nm968","article-title":"Autoimmunity is triggered by cPR-3(105\u2013201), a protein complementary to human autoantigen proteinase-3","volume":"10","author":"Pendergraft","year":"2004","journal-title":"Nature Med"},{"key":"10.1016\/j.berh.2004.11.003_bib39","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/art.1780360312","article-title":"Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis","volume":"36","author":"Kerr","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2004.11.003_bib40","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener granulomatosis: an analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2004.11.003_bib41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00002281-199801000-00006","article-title":"Evaluation, treatment, and prophylaxis of infections complicating systemic vasculitis","volume":"10","author":"Sneller","year":"1998","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.berh.2004.11.003_bib42","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/1529-0131(200103)44:3<666::AID-ANR116>3.0.CO;2-A","article-title":"Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg\u2013Strauss syndrome: analysis of four prospective trials including 278 patients","volume":"44","author":"Gayraud","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2004.11.003_bib43","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00005792-197311000-00002","article-title":"Wegener's granulomatosis: studies in eighteen patients and a review of the literature","volume":"52","author":"Fauci","year":"1973","journal-title":"Medicine"},{"key":"10.1016\/j.berh.2004.11.003_bib44","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0002-9343(90)90367-M","article-title":"Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide","volume":"89","author":"Hoffman","year":"1990","journal-title":"Am J Med"},{"key":"10.1016\/j.berh.2004.11.003_bib45","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/art.1780370622","article-title":"Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis","volume":"37","author":"Reinhold-Keller","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2004.11.003_bib46","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/art.1780401213","article-title":"A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis","volume":"40","author":"Guillevin","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2004.11.003_bib47","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/ndt\/16.10.2018","article-title":"The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review","volume":"16","author":"de Groot","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.berh.2004.11.003_bib48","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/ndt\/15.5.611","article-title":"Wegener's granulomatosis: clinical course in 108 patients with renal involvement","volume":"15","author":"Aasarod","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.berh.2004.11.003_bib49","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/art.10459","article-title":"High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate","volume":"47","author":"Reinhold-Keller","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2004.11.003_bib50","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","article-title":"Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years","volume":"98","author":"Fauci","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2004.11.003_bib51","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/art.20234","article-title":"Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis","volume":"51","author":"Slot","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2004.11.003_bib52","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/art.1780380505","article-title":"Analysis of 42 Wegener's granulomatosis patients treated with methotrexate and prednisone","volume":"38","author":"Sneller","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2004.11.003_bib53","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0889-857X(05)70363-X","article-title":"Methotrexate use in systemic vasculitis","volume":"23","author":"Langford","year":"1997","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.berh.2004.11.003_bib54","first-page":"492","article-title":"Induction of remission in Wegener's granulomatosis with low dose methotrexate","volume":"25","author":"de Groot","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2004.11.003_bib55","first-page":"1134","article-title":"Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice","volume":"26","author":"Stone","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2004.11.003_bib56","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1681\/ASN.V7133","article-title":"Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis","volume":"7","author":"Nachman","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.berh.2004.11.003_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/art.20921","article-title":"Implications of ANCA status when switching to maintenance therapy","author":"Hoffman","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2004.11.003_bib58","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F","article-title":"Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety","volume":"44","author":"Stone","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2004.11.003_bib59","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/41.10.1126","article-title":"Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients","volume":"41","author":"Bartolucci","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2004.11.003_bib60","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/rheumatology\/41.11.1303","article-title":"Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis","volume":"41","author":"Lamprecht","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2004.11.003_bib61","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W","article-title":"Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy","volume":"44","author":"Specks","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2004.11.003_bib62","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-129-5-199809010-00004","article-title":"Interferon-alpha treatment of four patients with the Churg\u2013Strauss syndrome","volume":"129","author":"Tatsis","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2004.11.003_bib63","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1078\/0171-2985-00197","article-title":"Treatment of refractory Churg\u2013Strauss-syndrome (CSS) by TNF-alpha blockade","volume":"206","author":"Arbach","year":"2002","journal-title":"Immunobiology"},{"key":"10.1016\/j.berh.2004.11.003_bib64","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J","article-title":"An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients","volume":"43","author":"Reinhold-Keller","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2004.11.003_bib65","first-page":"467","article-title":"Microscopic polyarteritis: presentation, pathology and prognosis","volume":"56","author":"Savage","year":"1985","journal-title":"QJM"},{"key":"10.1016\/j.berh.2004.11.003_bib66","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/1529-0131(199904)42:3<421::AID-ANR5>3.0.CO;2-6","article-title":"Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients","volume":"42","author":"Guillevin","year":"1999","journal-title":"Arthritis Rheum"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694204001640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694204001640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T01:51:50Z","timestamp":1683078710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694204001640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["S1521694204001640"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2004.11.003","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}